Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France.
(2016) mAbs — Vol. 8, n° 6, p. 999-1009 (2016)
Files
boreal_174768.pdf
Open Access - Adobe PDF
- 424.17 KB
Details
- Authors
- Abstract
- Monoclonal antibody (mAb) therapeutics have tremendous potential to benefit patients with lung diseases, for which there remains substantial unmet medical need. To capture the current state of mAb research and development in the area of respiratory diseases, the Research Centre of Respiratory Diseases (CEPR-INSERM U1100), the Laboratory of Excellence "MAbImprove", the GDR 3260 "Antibodies and therapeutic targeting", and the Grant Research program ARD2020 "Biotherapeutics" invited speakers from industry, academic and government organizations to present their recent research results at the Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current challenges and perspectives congress held March 31 - April 1, 2016 in Tours, France.
- Affiliations
Citations
Desoubeaux, G., Reichert, J. M., Sleeman, M., Reckamp, K. L., Ryffel, B., Adamczewski, J. P., Sweeney, T. D., Vanbever, R., Diot, P., Owen, C. A., Page, C., Lerondel, S., Le Pape, A., & Heuze-Vourc’h, N. (2016). Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France. mAbs, 8(6), 999-1009. https://doi.org/10.1080/19420862.2016.1196521 (Original work published 2016)